Trade State Street SPDR S&P Biotech ETF - XBI CFD
What is State Street SPDR S&P Biotech ETF (XBI)?
The State Street SPDR S&P Biotech ETF is an exchange-traded fund designed to provide investment results that correspond generally to the total return performance of the S&P Biotechnology Select Industry Index. The fund focuses on companies primarily involved in the biotechnology sector, including firms engaged in research, development, and manufacturing of biotechnological products and services. It offers diversified exposure to a range of biotechnology companies, spanning various stages of development and market capitalization. The ETF is managed by State Street Global Advisors, a prominent asset management firm. It serves as a tool for investors seeking targeted exposure to the biotechnology industry within the broader healthcare sector. The fund's portfolio typically includes companies involved in areas such as genetic research, molecular biology, and pharmaceutical development. As an index-based fund, it aims to replicate the performance of its underlying index by holding a representative sample of its constituent securities.
State Street SPDR S&P Biotech ETF Stock Price Today: Live Overview
The price today is shaped by active market participation with State Street SPDR S&P Biotech ETF trading at $128.66. The intraday price range lies between $124.61 and $129.87, accompanied by a daily change of -0.0078%.
FAQ: State Street SPDR S&P Biotech ETF (XBI)
What is the current price of XBI stock?
The latest trading value is $128.66.
Does XBI pay dividends?
This ETF pays dividends via cash distributions (if applicable).
Does XBI have a formal corporate presence or regional headquarters in the UAE?
The fund does not have an official UAE office or subsidiary and operates through distributors.
What is XBI best known for?
The ETF is most famous for tracking biotechnology companies in the S&P index.
What assets are typically shown together with XBI?
Commonly shown alongside XBI: YieldMax NVDA Option Income Strategy ETF, BioArctic AB, National Retail Prop
Latest shares articles



